Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-08 10:26 am Sale | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Empery Asset Management LP | 151,654 2.650% | -54,969 (-26.60%) | Filing History |
| 2023-06-16 4:04 pm Purchase | 2023-06-09 | 13G | X4 Pharmaceuticals, Inc. XFOR | Integrated Core Strategies (US) LLC | 275,627 5.200% | 275,627 (New Position) | Filing History |
| 2023-05-26 3:03 pm Purchase | 2023-05-18 | 13D | X4 Pharmaceuticals, Inc. XFOR | Growth Equity Opportunities 18 VGE, LLC | 524,760 9.990% | 120,200 (+29.71%) | Filing History |
| 2023-02-14 5:24 pm Purchase | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 344,288 8.200% | 283,077 (+462.46%) | Filing History |
| 2023-02-14 4:18 pm Sale | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Point72 Asset Management, L.P. | 30,441 1.300% | -23,999 (-44.08%) | Filing History |
| 2023-02-14 11:26 am Sale | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Ikarian Capital LLC | 11,638 0.300% | -63,845 (-84.58%) | Filing History |
| 2023-02-14 06:34 am Purchase | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Bain Capital Life Sciences Fund, L.P. | 406,750 11.000% | 310,532 (+322.74%) | Filing History |
| 2023-02-13 5:51 pm Sale | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BIOTECHNOLOGY VALUE FUND L P | 75,280 1.900% | -25,642 (-25.41%) | Filing History |
| 2023-01-13 08:02 am Purchase | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Empery Asset Management LP | 206,623 5.120% | 206,623 (New Position) | Filing History |
| 2022-12-19 5:31 pm Purchase | 2022-12-09 | 13D | X4 Pharmaceuticals, Inc. XFOR | Growth Equity Opportunities 18 VGE, LLC | 404,560 9.990% | 175,288 (+76.45%) | Filing History |
| 2022-07-19 5:28 pm Purchase | 2022-07-06 | 13D | X4 Pharmaceuticals, Inc. XFOR | Growth Equity Opportunities 18 VGE, LLC | 229,272 9.900% | 229,272 (New Position) | Filing History |
| 2022-02-14 4:43 pm Sale | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Ikarian Capital LLC | 75,483 8.100% | -12,017 (-13.73%) | Filing History |
| 2022-02-14 4:38 pm Purchase | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Point72 Asset Management, L.P. | 54,440 5.800% | 4,432 (+8.86%) | Filing History |
| 2022-02-14 4:11 pm Sale | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | RA Capital Management, L.P. | 37,867 3.900% | -20,401 (-35.01%) | Filing History |
| 2022-02-14 1:02 pm Purchase | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BIOTECHNOLOGY VALUE FUND L P | 100,922 9.990% | 43,602 (+76.07%) | Filing History |
| 2022-02-14 06:39 am Purchase | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Bain Capital Life Sciences Fund, L.P. | 96,218 11.000% | 41,269 (+75.10%) | Filing History |
| 2022-02-11 5:08 pm Purchase | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 61,212 6.400% | 12 (+0.02%) | Filing History |
| 2022-02-11 3:17 pm Purchase | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Orin Hirschman | 51,053 6.200% | 2,423 (+4.98%) | Filing History |
| 2022-01-19 11:05 am Purchase | 2022-01-14 | 13G | X4 Pharmaceuticals, Inc. XFOR | Lincoln Park Capital Fund LLC | 60,336 6.440% | 60,336 (New Position) | Filing History |
| 2021-11-17 5:27 pm Purchase | 2021-11-09 | 13G | X4 Pharmaceuticals, Inc. XFOR | Point72 Asset Management, L.P. | 50,008 5.600% | 50,008 (New Position) | Filing History |